Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in the Netherlands

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 8-16

  Franken, Margreet G ^a   Van Gils, Chantal W M ^a   Gaultney, Jennifer G ^a   Delwel, Gepke O ^b   Goettsch, Wim ^b   Huijgens, Peter C ^c   Steenhoek, Adri ^a   Punt, Cornelis J A ^d   Koopman, Miriam ^e   Redekop, William K ^a   Uyl De Groot, Carin A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Health Care Insurance Board ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bortezomib; Everyday practice; Evidence development; Feasibility; Outcomes research; Oxaliplatin; Real world data

Indexed keywords

BORTEZOMIB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG USE; FEASIBILITY STUDY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; NETHERLANDS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84871416838     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.010     Document Type: Article

References (34)

1. C. Carbonneil, F. Quentin, and S.H. Lee-Robin A common policy framework for evidence generation on promising health technologies Int J Technol Assess Health Care 25 Suppl. 2 2009 56 67
2. L.P. Garrison, P.J. Neumann, P. Erickson, D. Marshall, and C.D. Mullins Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report Value Health 10 2007 326 335 (Pubitemid 47481104)
3. J. Hutton, P. Trueman, and C. Henshall Coverage with evidence development: an examination of conceptual and policy issues Int J Technol Assess Health Care 23 2007 425 432 (Pubitemid 47586920)
4. T. Stafinski, C.J. McCabe, and D. Menon Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems Pharmacoeconomics 28 2010 113 142
5. A. Briggs, K. Ritchie, E. Fenwick, K. Chalkidou, and P. Littlejohns Access with evidence development in the UK: past experience, current initiatives and future potential Pharmacoeconomics 28 2010 163 170
6. M. Klemp, K.B. Fronsdal, and K. Facey What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 27 2011 77 83
7. P.E. Mohr, and S.R. Tunis Access with evidence development: the US experience Pharmacoeconomics 28 2010 153 162
8. S.R. Tunis, and S.D. Pearson Coverage options for promising technologies: medicare's 'coverage with evidence development' Health Aff 25 2006 1218 1230 (Pubitemid 44497620)
9. C. Gatsonis The promise and realities of comparative effectiveness research Stat Med 29 2010 1977 1981
10. P. Sullivan, and D. Goldmann The promise of comparative effectiveness research JAMA 305 2011 400
11. H.M. Krumholz Outcomes research: generating evidence for best practice and policies Circulation 118 2008 309
12. C.M. Clancy, and J.M. Eisenberg Outcomes research: measuring the end results of health care Science 282 1998 245
13. J. Lipscomb, M.S. Donaldson, and R.A. Hiatt Cancer outcomes research and the arenas of application J Natl Cancer Inst Monogr 33 2004 1 7
14. D.B. Rubin On the limitations of comparative effectiveness research Stat Med 29 2010 1991 1995
15. S.R. Tunis, J. Benner, and M. McClellan Comparative effectiveness research: policy context, methods development and research infrastructure Stat Med 29 2010 1963 1976
16. N.A. Dreyer, S.R. Tunis, M. Berger, D. Ollendorf, P. Mattox, and R. Gliklich Why observational studies should be among the tools used in comparative effectiveness research Health Aff 29 2010 1818
17. K. Chalkidou, S. Tunis, and R. Lopert Comparative effectiveness research and evidence based health policy: experience from four countries Milbank Q 87 2009 339 367
18. E. Cox, B.C. Martin, T. Van Staa, E. Garbe, U. Siebert, and M.L. Johnson Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the international society for pharmacoeconomics and outcomes research good research practices for retrospective database analysis task force Report - Part II Value Health 12 2009 1053 1061
19. M. Berger, M. Mamdani, D. Atkins, and M. Johnson Good research practices for comparative effectiveness research: defining, reporting and interpreting non-randomized studies of treatment effects using secondary data sources. ISPOR TF report 2009 - Part I Value Health 12 2009 1044 1052
20. J. Kupersmith, and A.K. Ommaya The past, present, and future of comparative effectiveness research in the US department of veterans affairs Am J Med 123 2010 e3 e7
21. J. Concato, E.V. Lawler, R.A. Lew, J.M. Gaziano, M. Aslan, and G.D. Huang Observational methods in comparative effectiveness research Am J Med 123 2010 e16 e23
22. M.L. Johnson, W. Crown, B.C. Martin, C.R. Dormuth, and U. Siebert Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force Report - Part III Value Health 12 2009 1062 1073
23. B.M. Psaty, and D.S. Siscovick Minimizing bias due to confounding by indication in comparative effectiveness research JAMA 304 2010 897 898
24. C. Sorenson, H. Naci, J. Cylus, and E. Mossialos Evidence of comparative efficacy should have a formal role in European drug approvals BMJ 343 2011 d4849
25. H.M. Krumholz Real-world imperative of outcomes research JAMA 306 2011 754
26. S.R. Tunis, and K. Chalkidou Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al. Int J Technol Assess Health Care 23 2007 432 435 (Pubitemid 47586924)
27. D.A. Revicki, and L. Frank Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies Pharmacoeconomics 15 1999 423 434 (Pubitemid 29210946)
28. M.R. Kuijpers, and W.G.M. Toenders Assessment procedure for inpatient drugs [in Dutch: procedure beoordeling intramurale geneesmiddelen] 2006 Diemen College voor Zorgverzekeringen [Report No.: 26022597]
29. G.O. Delwel Guidance for outcomes research 2008 Diemen College voor Zorgverzekeringen [Report No.: 270]
30. H.M. Lokhorst, I. Schmidt-Wolf, and P. Sonneveld Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma Haematologica 93 2008 124 127 (Pubitemid 351156161)
31. C.W.M. Van Gils, M. Koopman, L. Mol, W.K. Redekop, C.A. Uyl-de Groot, and C.J.A. Punt Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in the Netherlands Acta Oncol 51 2012 57 64
32. M.G. Franken, J.G. Gaultney, P.C. Huijgens, W.K. Redekop, and C.A. Uyl-de Groot Treatment variation complicates real-world pharmacoeconomics: daily clinical practice of bortezomib in relapsed or refractory multiple myeloma. Value Health 12 2009 A225 [Abstract CN7]
33. J.G. Gaultney, M.G. Franken, C.W.M. van Gils, P.C. Huijgens, W.K. Redekop, and C.A. Uyl-de Groot Outcomes research of bortezomib indicated for multiple myeloma in the context of the Dutch reimbursement policy for expensive medicines: threats to the internal validity of the incremental effectiveness estimate Value Health 12 2009 A259 [Abstract PCN18]
34. B.J. Byrne, P.S. Kishnani, and L. Case Pompe disease: design, methodology, and early findings from the Pompe registry Mol Genet Metab 103 2011 1 11